Skip to main content

Glucagon News

FDA Medwatch Alert: Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of Glucagon® Emergency Kit Due to Loss of Potency

INDIANAPOLIS, Sept. 24, 2021 -- Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, ...

Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke Kit for the Treatment of Severe Hypoglycemia

First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue Gvoke HypoPen®, Gvoke® PFS, and Gvoke® Kit – three different administration options to accommodate pati...

FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

CHICAGO--(BUSINESS WIRE)--Sep. 10, 2019-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...

FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia

July 24, 2019 – The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Hypoglycemia

Glucagon patient information at Drugs.com